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Summary 
 Lung cancer is one of the leading causes of death globally and it is the most common 
cancer worldwide [1]. Seventy-five percent of cases are non-small cell lung cancer (NSCLC). 
Treatment of NSCLC has been challenging due to the limited knowledge of its pathological 
mechanisms and only a small number of treatments for the illness’ advanced stages [2].  
 Epidermal growth factor receptor (EGFR) tyrosine kinase protein has recently been 
determined to be responsible for the generation of tumors, cell division and suppression of cell 
death. The normal function of EGFR includes transmitting the signals inside the cell through 
various pathways which result in growth, development, and cell differentiation. EGFR is 
commonly found on the surface in many types of cells in a human body. However, it is detected 
in much greater quantities in numerous human malignancies, including NSCLC. Such 
discoveries resulted in the search for small molecule drugs that would inhibit EGFR thus 
eliminating cancer [2], [3].  
 Few small molecule inhibitors have been found to be successful in inhibition of 
intracellular tyrosine kinase domain of EGFR and were offered as treatments. For example, 
erlotinib for NSCLC and pancreatic cancer, and gefitinib to treat certain lung and breast cancers. 
However, growing resistance to the medication through mutations of EGFR accompanied by 
various adverse effects demanded another approach in inhibition. This led the scientists to 
reevaluate a long-feared domain of covalent drugs due to its previous history of toxicity [4], [5].  
 Covalent drugs are a type of drugs that form a covalent bond with a protein thus 
inhibiting its function. An ability to form an irreversible bond is one of the ways covalent drugs 
differ from conventional reversible drugs. Such a bond results in more effective drugs, which 
remain longer in the system and require lower dosage [6]. Despite the avoidance of drugs with a 
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covalent mechanism of action in fear of toxicity [7], covalent drugs such as Omeprazole, 
Acetaminophen, Amoxicillin, Pantoprazole, Aspirin, and Clopidogrel are included in the top 40 
best selling drugs in the US as of 2018 [8]. These medications treat various conditions ranging 
from acid reflux to bacterial infections and heart conditions. Such a positive impact on human 
health has motivated the development of small molecules with a covalent mechanism of action 
targeting EGFR [9].  
 In medicinal chemistry and drug design, computer simulations of reactions between small 
molecules and a protein of interest are frequently used to predict the outcome of their interaction 
and potential drug efficacy. Through the incorporation of various complex computer algorithms, 
the behavior of a protein and a potential drug can be predicted with some percent error. Such 
information is further translated into the organic synthesis laboratory, where the molecule is 
produced and is further tested in vivo.  
This project specifically focuses on potential ways to improve currently available tools 
for the prediction of the behavior of covalent inhibitors in ICM-Pro. ICM-Pro by Molsoft is a 
software providing a desktop environment for a detailed analysis of the structure and function of 
various molecules [10]. The outcome of this study can potentially reduce percent error in 
computational studies which can significantly improve in vitro experiments thus lowering the 
laboratory costs of such research and creating new ways to target cancer.  
This project is a culmination of one semester of data collection at NYU Langone Medical 
Center followed by a second semester of data analysis, its interpretation, and writing.  
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Abstract 
 The goal of this project was to investigate the complex mechanism of covalent bonding 
among different molecules and their targets in a modeling software ICM-Pro. Specifically, it 
included the identification of fundamental aspects of a covalent bonding mechanism of the 
Michael addition reaction. Michael addition reaction of electrophilic α, β-unsaturated carbonyl 
compounds with a nucleophilic cysteine residue in thymidylate synthase, papain, and EGFR 
tyrosine kinase were examined. Thymidylate synthase and EGFR were chosen because they are 
important targets in the treatment of various types of cancer. In order to find the most optimal 
parameters, identification and assessment of the effect of the pre-bonding features such as 
distance, angle and dihedral angle, which have not previously been exploited, and their accuracy 
in the refinement of covalent docking simulation results was performed. The validity of results 
was determined through the comparison of the data obtained through noncovalent, covalent and 
4D docking of a set of molecules in a virtual environment to the experimentally determined 
measures of binding affinity, IC50 and Ki values. The statistical analysis showed no linear 
relationship between the covalent docking score and any of the aforementioned pre-bonding 
features equally among binders and nonbinders. One-sided t-test analysis indicated that binders 
are significantly closer positioned to the cysteine residue in a noncovalent setting than 
nonbinders (p = 0.0296). Such findings can be further used to analyze the molecules in a docking 
setting with distance restraints and may contribute to a currently existing computational 
algorithm in ICM-Pro. The feature additionally can be used for the analysis of large datasets of 
molecules and can be further incorporated to improve prediction scores for covalent inhibitors 
screening protocol. Consequently, more accurate elimination of potential false positives and false 
negatives can lead to breakthroughs in a field of targeted covalent inhibitors.  
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1. Introduction  
Molecules are formed when a group of atoms is held together by covalent bonds. 
Covalent bonds are formed by a shared pair of electrons, which occur when non-metal atoms 
combine and electrostatic interactions take place (Figure 1). This results in the 
 
 
 
 
Figure 1. Graphical representation of a covalent bond formation between two hydrogen atoms.  
1 – each electron is held by the positively charged nucleus, hydrogens are free-floating; 2 – 
electrons are attracted to the proton of the other hydrogen as they approach each other; 3 – 
sharing of electrons results in an H2 molecule connected through a covalent bond. 
superimposition of the outermost atomic orbitals in a way that allows for the bonding atoms to 
form molecular orbitals where they share their electrons while overcoming the repulsive forces 
of like-charged particles. The distance and angle at which atoms approach each other are 
important for the covalent bond formation. For example, if the atoms are too far apart, the 
attractive forces are small, and no bond exists. Likewise, if the atoms are too close, the repulsive 
forces of the nuclei push the atoms apart [11].  
Atoms bonded by covalent bonds can create a substantial amount of various stable 
molecular compounds. For example, amino acids are made of one amino and one carboxyl 
functional groups all bonded to the same carbon atom along with a specific side chain different 
in each amino acid. Many amino acids linked together make up large biological molecules called 
proteins (Figure 2).  
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Figure 2. Comparison of size between amino acid Cysteine-797 (C797) and a protein: A – close-
up view as a part of an EGFR tyrosine kinase protein (PDB ID: 3w32 [12]); B – C797 shown 
with a whole subunit.  
A protein’s structure is dependent on the specific biological function it performs in the 
body. Enzymes are proteins that accelerate the rate of a biological reaction and are frequently 
targeted by drugs in order to inhibit a certain reaction.   
Enzymes have a unique property called specificity. It is determined by the enzyme’s 
active site – a pocket of a specific shape and chemical composition within an enzyme (Figure 3). 
Such an open structure attracts and holds its substrate, a reactant in an enzyme-catalyzed 
reaction, by using various forces until the reaction 
is completed and the products are released. Such 
forces originate from amino acid side chains 
located in the active site. They involve 
noncovalent, intermolecular forces which include 
variations of electromagnetic interactions and, 
sometimes, a temporary covalent bond.  
Figure 3. Active site pocket of EGFR tyrosine kinase (PDB ID: 3w32 [12]) represented in violet.  
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Drugs that slow down or stop the function of an enzyme are called inhibitors.  An 
enzyme can be temporarily disabled by either a reversible inhibition or permanently inactivated 
by irreversible inhibition that requires the production of new enzymes. The three main ways to 
inhibit an enzyme are through uncompetitive, competitive, or mixed inhibition. Uncompetitive 
inhibition operates through the binding of the inhibitor to the enzyme-substrate complex that 
ultimately either slows down the reaction or stops it altogether. On the other hand, a competitive 
inhibitor acts like a substrate and binds to the active site of the enzyme thus preventing the 
substrate from entering the active site and undergoing the reaction [11]. Such inhibition can be 
obtained through both noncovalent binding and covalent bonding of the inhibitor to the active 
site. This project focused on covalent drugs or targeted covalent inhibitors, which are designed to 
react with their target proteins or enzymes by first binding noncovalently and afterward 
establishing a covalent bond with a specific residue in the active site of the protein. Such 
irreversible inhibition renders the enzyme unavailable to the substrate and marked for future 
degradation thus providing an alternative treatment for cancer.   
1.1 History of targeted covalent inhibitors 
The concept of atoms sharing electrons first appeared in 1916 when Gilbert N. Lewis first 
presented the Lewis dot structure [13]. This system of representation of valence electrons from 
the outermost shell of atoms since then simplified the concept of bonding of atoms in a molecule. 
By providing specific rules it allowed to explain the chemical behavior of molecules along with 
the existence of multiple covalent bonds.  
Long before the idea of covalent bonds appeared in scientific literature, the drugs forming 
covalent bonds to its targets, although not recognized at the time, were of great help. It all started 
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with the synthesis of acetylsalicylic acid by a talented French chemist Charles Frédéric Gerhardt 
in 1853, which was further reproduced by Bayer in the 1890s and named as Aspirin. This 
discovery led to a globally consumed drug with more than 50 billion pills taken each year [14]. 
Since then, many more medications have come into our quotidian routine, which are nowadays 
familiar and available to most of the population. For instance, Penicillin, an antibiotic that is used 
to treat infections [15], and Omeprazole which is used to alleviate the consequences of excess 
acid in the stomach by reducing its secretion [16]. 
Even though some of the covalent drugs eventually succeeded on the market and earned 
blockbuster status, the resources of the scientific community were not always aimed at 
discovering more medications with a similar mode of action [6]. This largely stemmed from the 
study done by Jollow et al. in 1973 that detected that large doses of acetaminophen led to  
necrosis of liver tissues through covalent bonding of the highly reactive acetaminophen 
intermediate to the liver proteins [7]. Such discovery supported the reluctance of drug discovery 
programs to research covalent drugs with electrophilic functional groups.  
In spite of concerns regarding the potential toxicity of covalent drugs, researchers have 
often utilized natural products with electrophilic groups as therapeutics.  Such products are often 
found in living organisms since many protein targets contain amino acids with accessible 
nucleophilic side chains in the active site. For instance, serine, lysine, histidine, and cysteine. 
The features of natural products with electrophilic moieties targeting nucleophilic residues on 
their target proteins lead to the discovery of antifungals, antibiotics and anticancer agents [9].  
With the advancements of computer-aided drug design programs, it has become possible 
to design, adjust, and test potential covalent inhibitors in the virtual environment, which 
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ultimately led to the discovery of many anticancer agents already used today and some in late 
stages of clinical trials [9].  
1.2 Reaction mechanism of covalent inhibitors  
Inhibition of the protein by a covalent drug usually includes 2 steps (Figure 4). First, a 
small ligand (I) is modified in a way that allows its relatively reactive electrophile to bind closely 
to a specific nucleophile in the active site of a protein (E). Through conventional reversible 
interactions, a non-covalent complex (EI) is formed (Figure 4, a). The second step involves a 
covalent bond formation between a ligand and a protein that results in an inhibited complex (E-
I). Such a complex can be long-lasting and, ultimately, irreversible within the turnover of the 
target protein. Because irreversible inhibitors, in theory, can manage to fully neutralize an 
enzyme if given enough time, such compound does not follow conventional equilibrium kinetics 
[6], [17] 
 
Figure 4. Comparison of an inhibitor (I) interacting with an enzyme (E) under (A) traditional 
non-covalent and (B) covalent binding modes.  
 
IC50 values are a way to understand numerically the ability of a drug to inhibit an enzyme. 
IC50 stands for how much of a drug is required to inhibit an enzyme by 50% [18]. Although it is 
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frequently used to measure the potency of reversible inhibitors, the ratio between the rate of 
enzyme inhibition (kinact) and the inhibition constant (Ki) is also used with covalent irreversible 
inhibitors. Since traditional IC50 values can be time-dependent, the kinact:Ki ratio is favored over IC50 
for ranking prospective covalent inhibitors.   
A combination of both covalent and noncovalent mechanism of action of a drug allows to 
design a potent inhibitor with conservatively modified reactivity and defined reciprocity to the 
target protein. Such covalent drugs are known as suicide or mechanism-based inhibitors. Their 
mode of action includes a precise attack on a catalytic nucleophile in the active site of the 
enzyme that irreversibly inactivates it. For example, the covalent drug Penicillin is a suicide 
inhibitor that treats bacterial infections through the irreversible binding to a serine residue and 
formation of a stable ester in bacterial transpeptidase [15].  
1.3 Common reactions used in covalent inhibition 
There are many chemical reactions that have been used to covalently modify protein 
targets for medicinal applications. Among the most frequently used ones are: Michael addition 
(used in 45% of all drug design approaches), addition to nitrile (23%), addition to aldehyde 
(12%), nucleophilic substitution (8%), addition to ketone (6%), ring opening (4%), and disulfide 
bond formation (2%) [19]. Since Michael addition has been used most frequently, a sufficient 
number of datasets were identified to test whether the values of distance, angle and a dihedral 
angle between a cysteine residue and a molecule could be used to distinguish binders from non-
binders.  
Michael addition reaction includes the nucleophilic addition of a carbanion or another 
nucleophile to an a,b-unsaturated carbonyl compound [20]. Acrylamide is one of the most 
widely used reactive groups, a so-called warhead, used to target non-catalytic cysteine residues 
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among targeted covalent inhibitors. An acrylamide substituent in a,b-unsaturated carbonyls 
favors a reaction in a 1,4-fashion with nucleophilic thiolates found in cysteine residues (Figure 
5). Specifically, an attack of the b-carbon (position 1) by nucleophilic sulfur and subsequent 
hydrogen transfer first to the oxygen (position 4) and then to the a-carbon resulting in a 
thermodynamically stable compound [21].  
  
Figure 5. Michael addition reaction of the ligand to the cysteine residue of the protein resulting 
in a covalent inhibition.  
 
Such a reaction is currently widely utilized in the design of covalent inhibitors targeting non-
catalytic Cysteine-797 (C797) located in the active site of the EGFR family of tyrosine kinases 
[9].  
1.4 Advantages and Disadvantages of covalent inhibitors  
The main reason preventing researchers and developers from investigating covalent 
inhibitors for many years arose from safety concerns regarding two main classes of medicinal 
compounds, which can alter cellular proteins. The first class of compounds includes drugs that 
have a reactive electrophilic group in the parent structure (e.g. penicillin). The second class 
contains drugs that go through biotransformation when taken by an organism that results in a 
reactive electrophile that can readily react with circulating nucleophiles such as liver proteins 
(e.g. acetaminophen). The study of the effect of gram quantities of acetaminophen revealed 
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severe hepatoxicity in humans that was linked to an N-acetyl-p-benzoquinone imine, which is a 
major metabolite of acetaminophen. Since then the possibility of an off-target reactivity and the 
formation of reactive drug metabolites that lead to tissue damage or may elicit an immune 
response has been considered as a liability in drug development [7], [9].  
There are many advantages covalent inhibitors have to offer over conventional 
noncovalent inhibitors. For instance, carefully designed covalent warheads that are able to access 
rare, poorly conserved residues of a specific target protein. Such an advantage allows for the 
development of a highly selective inhibitor. Additionally, covalent drugs have been used to 
target proteins with a narrow binding cleft. Due to the formation of a covalent bond between the 
inhibitor and the target, covalent drugs also have a high binding affinity. Subsequently, they also 
have stronger potency at the same time as a small molecular size, which is favored for medicinal 
purposes [22]. Moreover, covalent inhibition can be effectively irreversible which results in long 
residence time in the active site of the protein. In this case, new protein synthesis is required to 
restore a particular activity which means the drug will be effective for a longer period of time 
[6].  
1.5 Recent breakthroughs among targeted covalent inhibitors 
Although commonly neglected by pharmaceutical companies, there are many FDA 
approved covalent drugs available nowadays for the treatment of diverse clinical conditions. For 
example, anti-infective Rochephin; Narlaprevir for the treatment of Hepatitis C Virus; Warfarin 
to prevent blood clots; Proscar for hair loss in men; Selegiline to help with symptoms of 
Parkinson’s disease; Bortezomib for myeloma and mantle cell lymphoma; and many more 
medications targeting various types of cancer [9]. The effectiveness of these drugs has restored 
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interest into a covalent mechanism of action as reported by the discoveries of novel covalent 
drugs and active research performed in the field [6].  
2. EGFR tyrosine kinase: role of structure and its function in drug development 
2.1 What is EGFR and its normal function 
EGFR or epidermal growth factor receptor is a 170-kd 
transmembrane glycoprotein which is a part of three other 
members belonging to the same ErbB family of tyrosine 
kinase receptors (RTK). Resembling all RTKs, EGFR consists 
of a significant extracellular receptor region followed by a 
transmembrane domain, intracellular juxtamembrane region, a 
tyrosine kinase domain and autophosphorylation domains 
(Figure 6).   
Figure 6. Structure of EGFR.  
EGFR is made of 1186 amino acids and is expressed on the surface of most normal cells. 
In fact, about 4´104 to 1´106 receptors can be found per cell. Such a high number corresponds to 
crucial functions of EGFR in a cell: stimulations of differentiation and proliferation of the cells 
by activating a signal-transduction cascade. Binding of specific ligands at the extracellular region 
results in a sequence of structural modifications. This leads to allosteric activation and further 
autophosphorylation of the EGFR tyrosine kinase domain. Once phosphorylated, tyrosine kinase 
residues provide binding sites for signal transducers and activators within the cell. For instance, 
the Ras-Raf pathway responsible for the regulation of DNA synthesis, cell growth, angiogenesis 
and inhibition of apoptosis. EGFR is believed to be crucial for epithelial tissue development, 
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homeostasis and motility and its protein tyrosine kinase plays a pivotal part in cell differentiation 
and proliferation [4], [23].  
2.2. Role of EGFR in cancer.  
Normally, the activity of EGFR and its signaling pathways are regulated through various 
mechanisms both intra- and extra-cellularly. However, abnormal receptor activation can take 
place when these mechanisms malfunction. For example, loss of negative regulatory 
mechanisms, gene amplification, mutations and overexpression of either ligands or receptors all 
lead to aberrant activity of EGFR.  
Overexpression of the EGFR receptor triggers intense signaling and activation of 
downstream pathways leading to cells with a high rate of growth and invasive features. This 
frequently leads to the growth of solid tumors and results in various types of cancers such as 
colon cancer, breast cancer, non-small-cell-lung cancer (NSCLC), etc. It has been noted that 
tumors with squamous cell histology, on average, test positive for EGFR in 84% cases [4]. 
Furthermore, EGFR has been associated with more aggressive disease and a reduced number of 
good outcomes in epithelial tumors [23]. Because of this, EGFR makes a valuable drug target.   
2.3 EGFR as a drug target.  
Several ways have been developed to target cancer caused by overexpression of EGFR. 
The large size of EGFR and the presence of both extracellular and intracellular domains allowed 
for the development of various methods of its deactivation by interfering with EGFR-mediated 
cellular effects. For example, several monoclonal antibodies have been developed that target the 
extracellular region and thus deactivate the signaling pathways from outside of the cell [23]. 
Such inhibition requires lower concentration and results in greater specificity for the EGFR. 
However, if the person develops an immune-antibody response, the therapy would become 
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ineffective. Additionally, monoclonal antibodies are less effective against mutations or variations 
in the extracellular domain as they fail to recognize them [4].   
In order to target EGFR from within the cell, small molecules tyrosine kinase inhibitors 
have been developed to bind both reversibly and irreversibly to the ATP-binding site of the 
EGFR kinase domain. For example, highly selective non-competitive reversible inhibitor 
Gefitinib (ZD1839) showed significant antiproliferative effects at a low dosage (50% inhibitory 
concentration of 23 nmol/L). Likewise, Erlotinib (OSI-774) is another drug successfully applied 
in the treatment of NSCLC with oncogenic EGFR mutations (50% inhibitory concentration of 20 
nmol/L) [4]. However, severe adverse effects caused by the inhibitor of WT EGFR and the 
appearance of a second-site mutation in the EGFR kinase domain (T790M) after treatment 
rendered those first-generation inhibitors a liability and required the development of new drugs 
[5].   
2.4 Challenges of drug development or target the “undruggable”.  
“Undruggable” is a term originated to define proteins that could not be targeted 
pharmacologically [24]. Although EGFR is believed to be a “druggable” target, many obstacles 
come into play during the design and administration of drugs thus requiring an innovative 
approach and development of new technologies.  
First-generation inhibitors described above used for the treatment of patients with 
NSCLC deliver outstanding response rate and the control of the disease. However, after 11-14 
months, they ultimately develop resistance to the drug, and their condition progresses, commonly 
accompanied by inhibition of the WT EGFR resulting in a pruritic rash. It has been discovered 
that drug-resistant NSCLC patients develop an additional mutation (T790M) along with the 
primary activating mutation. Such progress in the disease makes the inhibitor ineffective and 
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restores abnormal signaling [5]. Moreover, the treatment of solid tumors can be hindered by the 
presence of multiple resistance mutations suggesting several resistance mechanisms [24].  
To overcome the challenges of first-generation inhibitors that bind reversibly to the 
target, a strategy to develop a covalently bonded irreversible inhibitor was created. Such second-
generation inhibitors have an advantage of longer residence time in the active site of the pocket 
that requires the re-synthesis of kinase proteins to restore the inhibited signaling pathways. For 
instance, canertinib and afatinib, which inhibit WT EGFR through the covalent bond with C797, 
displayed greater cellular potency compared to first-generation inhibitors. However, their clinical 
efficacy is restricted by the dose-limiting toxicity linked to the inhibition of WT EGFR.  
In response to the aforementioned challenges, the third generation of highly potent 
covalent inhibitors of EGFR was proposed to spare or minimize the WT EGFR toxicities. Such 
irreversible inhibitors demonstrated high specificity to the T790M-containing double mutant 
(Figure 7) [5].  
 
Figure 7.  Examples of three generations of EGFR protein kinase inhibitors.  
In order to develop such potent molecules available to selectively bind to their targets, 
their design in silico and modeling studies are required. By using the software to predict the 
chemical behavior of molecules with their target proteins, lead compounds can be discovered, 
tested experimentally and modified to produce novel drugs addressing the challenges in the 
industry.  
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3. The use of computational methods in drug development.  
Computer-aided drug design (CADD) include in silico methods which are progressively 
being utilized in both educational establishments and in industry. Such methods explore the 
interactions between various molecules and investigate their structural properties and potential 
activities in great detail. Structure manipulations in a three-dimensional environment permit 
obtaining valuable information about molecules’ behavior and allow for the prediction of various 
applications [25].  
3.1 Commonly used methods 
CADD methods can be broadly categorized as ligand-based or structure-based methods. 
Ligand-based methods make use of the available information about molecules and predict 
behavior through chemical similarity searches and quantitative structure-activity relation 
(QSAR) models [26]. It is most commonly used for membrane protein targets in which little 
structural information exists.  
On the other hand, structure-based CADD is employed with target proteins for which 
high-resolution structural data is present. Such data allows the identification of interaction 
energies between the protein and the molecules tested that will ultimately result in a molecule 
that forms a strong bond with its target. If the method is successfully applied, the in-silico 
findings can result in the discovery of a novel compound, which further could be confirmed with 
in vitro and in vivo experiments [25].  
3.2 Mechanism used in ICM-Pro 
Molecular docking is an effective approach used in structure-based CADD. Its main goal 
is to predict the best structure of a ligand-protein complex through computation methods. 
Docking includes two interconnected steps in which it first samples various conformations of the 
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ligand in the chosen pocket of the protein, followed by assigning those conformations a score 
and ranking them. Ideally, the highest-ranked conformation is validated by the experimental 
results in such a way that the predicted ligand’s conformation closely matches the one obtained 
from the co-crystallized protein-ligand complex. In this case, the root-mean-square deviation 
(RMSD), which is a measure of the average distance between the atoms, between the predicted 
and actual conformations results in a value of less than 2Å (Angstroms), and the predicted 
conformation is deemed successful [27].   
Such success has been noted in the ICM product of Molsoft and therefore was the first 
choice for this experiment since it performed consistently well through various competitions and 
independent studies [19]. The most recent ICM D3R Docking challenge ranked ICM the first for 
average RMSD docking accuracy with reported 78% of the top score poses under 1Å and 91% 
under 2Å [28]. 
ICM-Pro of Molsoft uses the biased probability Monte Carlo method for searching the 
best conformation of the ligand. Monte Carlo method is a type of computational algorithm that 
relies on repeated random sampling to acquire numerical data. Specifically, it uses randomness 
to solve problems [29]. It works by the random selection of a conformation in the internal 
coordinate space, which from there selects a new random position which is independent of the 
previously selected one, however, consistent with a predefined continuous probability 
distribution [28]. Additionally, every step is assessed in terms of the overall energy and the step 
that is lower in energy is usually accepted. However, the algorithm allows crossing of the pre-set 
barrier of a local energy minimum thus preventing the system from getting trapped in the local 
energy minima, which subsequently contributes to the randomness of the method [27]. 
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Each conformation is ranked through an ICM scoring function that gives an estimate of 
the binding free energy between a ligand and a receptor. It is usually a function of various energy 
terms based on a force-field and weighted according to numerous parameters. The lower the 
ICM score, the better the chance that the tested molecule is a true binder [28].  
3.3 Noncovalent vs covalent docking 
Both noncovalent and covalent docking are types of molecular docking. Both docking 
setups recommend a protein with a compound bound and a high-resolution x-ray structure for 
more accurate predictions since ligand binding changes the conformation of the protein [28].  
Noncovalent docking involves finding the best conformation of the small molecule ligand 
in the receptor site of the protein and to approximate the strength of the protein-ligand 
noncovalent interactions (Figure 8, A) [22]. ICM-Pro docking method assesses the following 
interactions: van der Waals interactions for both a hydrogen atom probe and a heavy-atom probe, 
electrostatic interactions, hydrophobic bonds, and lone-pair-based potential, which indicates 
directional preferences in hydrogen bonding [28].   
A                  B 
 
Figure 8. Visual representation of molecule (A) docked noncovalently, (B) docked covalently to 
C797.  
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In contrast, covalent docking is a more complex type of molecular docking which in 
ICM-Pro requires additional input criteria. For instance, identification of a warhead of a ligand, 
selection of a residue of the protein and proper mechanism of their reaction. For this study, the 
Michael addition reaction was selected between the electrophilic acrylamide warhead of the 
small molecule ligand and the nucleophilic cysteine residue of thymidylate synthase (TS) and 
EGFR to form a covalent bond. Such docking forces the selected amino acid residue and the 
ligand into a covalent bond by modifying ligand’s structure (Figure 8, B). Ligand conformations 
are then sampled through Monte Carlo simulation and assigned a score [28]. 
3.4 Limitations of covalent docking 
The current ICM-Pro covalent docking algorithm evaluates energetics of the product of 
the covalent addition reaction to the protein [E-I] (Figure 4). In the current tool, any features 
preceding the product formation are not considered. Features that contribute to the formation of 
the molecule-protein complex [EI] and transition state of the reaction are omitted from the 
current protocol. Recent studies show that the pre-bonding step is important for the covalent 
reaction to occur [19], [30]. In fact, the best covalent inhibitors on the market have large Ki 
values (experimentally measured Ki values estimate the ability of the molecule to form a non-
covalent complex with the protein of interest). Non-covalent interactions play a crucial role in 
molecules’ ability to complex to the active site of the enzyme and position the molecule perfectly 
for the reaction to take place.  
3.5 The role of distance and angles in a pre-bonding step 
Noncovalent interactions play a crucial role in a pre-bonding step of the covalent bond 
formation. Although these types of interactions are generally weaker than covalent ones and have 
rather transient existence at physiological temperatures, if the small molecule ligand exhibits 
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affinity and molecular complementarity to the target protein, that is similar to a “lock and key” 
model, the ligand can “lock” itself in a highly stable protein-ligand complex through multiple 
noncovalent interactions, which can ultimately result in a covalent bond formation.  
For example, when two atoms approach each other closely, van der Waals interactions, a 
weak attractive force, are created. The strength of these interactions is reduced with increasing 
distance. Therefore, if the ligand’s electrophilic warhead is in close proximity to the nucleophilic 
cysteine residue of the protein, van der Waals attractive forces could bring it sufficiently closer 
and allow for covalent bond formation. More specifically, an acrylamide group as the Michael 
acceptor is weakly electrophilic and the covalent bond formation heavily relies on close 
proximity to the cysteine residue of the protein thus reducing side reactions with other thiols in 
the cell or other cysteines on proteins [3], [31].  
The recent in-silico investigations of various proteins bound to a covalent compound 
proposed a new method for the identification of an ideal trajectory and angle of the ligand 
towards the target residue (Cysteine) in the active site of the protein. By examining the high-
resolution x-ray structures of proteins and the mechanism of side chain placement and the 
conformation of the protein backbone, several positions of cysteine side chains were discovered 
that would be able to bond to the electrophilic warhead. Those positions of cysteine side chains 
were marked as electrophilic spheres of 1-2Å radius and used to fine-tune the covalent docking 
of the ligands and optimizing the ideal location for a covalent bond formation. Such modification 
along with in vitro studies allowed the estimation of an energetically preferred planar angle of 
the C-S-C bond between the cysteine residue and the ligand to be approximately 98 ° [9].  
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3.6 IC50 and Ki as experimental verification of in silico results.  
Half-maximal inhibitory concentration, or IC50, is a measure of the effectiveness of a 
compound. It specifies the concentration of a compound required to inhibit a certain biological 
function or process by half. It is frequently used in pharmacology to identify the most potent 
drugs. IC50 values are usually measured in micromolar (µM) or nanomolar (nM) concentration. 
Lower the IC50 value of a drug results in a more potent inhibitor. This measurement is particularly 
beneficial for the evaluation of potential therapeutics [18].  
Ki, or inhibitory constant, is another way used to evaluate the relative inhibitory potential 
of a compound. Unlike the IC50 value, Ki represents the equilibrium constant associated with a 
dissociation of the inhibitor-bound enzyme complex. In other words, it is reflective of the 
binding affinity of the inhibitor and measures the strength of the binding between the ligand and 
the target enzyme. The lower the Ki value, the tighter or stronger the bond is and the smaller the 
amount of a drug is needed to inhibit a target protein [32], [33].   
Because both values are obtained through the in-vitro experiments, they can be used to 
validate the results in this in silico project.  
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Methodology:  
1. Dataset selection:  
A series of training datasets were identified for thymidylate synthase (TS), papain, and 
EGFR tyrosine kinase proteins. Each dataset provided a list of molecules that were 
experimentally tested for the Michael addition reaction with a reactive cysteine residue in the 
target proteins. Each study evaluated the molecules and provided in vitro data that was used for 
comparison to the data obtained from the computer simulations.  
The first dataset was obtained from the study by Nonoo et al. with a short list of 
molecules that were experimentally validated as true positive and negative controls with 
measured relative reactivities of their warheads in relation to the thymidylate synthase protein 
[34]. Additionally, papain protein in the aforementioned study experimentally reported no 
covalent bond formations and was used as a negative control.  
The second dataset analyzed the kinetics of covalent inhibition of an oncogenic EGFR 
and supplied experimentally measured Kd/Ki values and IC50 values for a list of molecules [35]. 
The dataset was further expanded for the same type of EGFR-L858R/T790M mutant in order to 
provide a sufficient number for statistical analysis [5], [36], [37].  
Ligand structures from five datasets were drawn in ChemDraw Professional 16.0 and 
converted to SMILES also readable by ICM-Pro. SMILES stands for Simplified Molecular Input 
Line Entry System that allows to encode a chemical structure in a specific linear way easily 
recognizable by the computer programs [38]. 
2. Selection of Protein Structures 
Various crystallographic structures of human thymidylate synthase, papain, and EGFR-
L858R/T790M proteins were reviewed and evaluated in the Protein Data Bank (PDB) [39]. 
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Three protein structures of thymidylate synthase protein (PDB ID: 1F4B [40], 1F4G [40], 4KNZ 
[41]), one papain (PDB ID: 1PPN [42]), and five EGFR protein structures (PDB ID: 5UG8 [43], 
3W32 [12], 5EDP [44], 5FED [36], 5FEE [36]) were chosen due to their high resolution and 
unique conformation of the active site.  
3. ICM-Pro  
The selection of the ICM-Pro product of Molsoft for this particular study was guided by a 
recent published article by Scarpino et al. in the Journal of Chemical Information. The study 
evaluated six covalent docking tools available on the market and listed ICM-Pro as one of the top 
tools in the industry [19].  
3.1 Preparation for docking simulation 
The protein structure of interest was uploaded to ICM-Pro by using a related PDB code. 
Protein was converted to an ICM object by removing all surrounding domains unrelated to the 
ligand docking including water molecules, co-crystallized agents, and other protein subunits if 
present. Optimization of hydrogens was done to obtain the best hydrogen bonding network.  
Once the structure was converted, it was inspected by the ICM Pocket Finder method 
[45] that searches for potential ligand binding sites and identifies them as pockets. On average, 4 
pockets were found, each ranked based on various criteria. The pocket close to our residue of 
interest was selected for further docking.  
The docking setup began with setting up a receptor that is used for identifying binding 
site residues around the selected pocket of interest. After, in order to generate receptor maps the 
purple box representing the residues to be included for evaluation of docking was adjusted so 
that the pocket was surrounded by it and also large enough to encompass residues surrounding 
the pocket. That created a replica of the ICM object already modified for further docking.  
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3.2 Non-covalent docking 
The molecules, drawn in ChemDraw and converted to SMILES, were uploaded in the 
same ICM project file and converted into a chemical table. Once the receptor was set, the 
docking simulation was configured to dock the chemical table with thoroughness 10 (represented 
the length of the simulation) to increase the time spent on each ligand for improved accuracy. 
Additionally, 2 best conformations of the ligand and racemic centers were investigated by the 
simulation.  
Once the simulation was completed, the results were displayed in a table with each ligand 
displaying the best 2 conformations ranked by an ICM docking score. The lower the score, the 
higher are the chances of the existence of that conformation. The data tables were exported into 
Microsoft Excel for further addition of the data (Results section).  
 The docking scores among 2 conformations available for each ligand were inspected. If 
the difference between the scores was <1, both conformations were used for further analysis. If 
the difference was >1, only the best scoring conformation remained in the table.  
 Once the best conformations were selected, each conformation was examined in the 
virtual environment and the following data were collected (Figure 9): the distance between C1 of 
the acrylamide warhead of the ligand and sulfur atom of the cysteine residue (C146 for TS, and 
C797 for EGFR) (Figure 9, A), the angle between a sulfur atom of cysteine residue and C1 and 
C2 of the ligand (Figure 9, B), and dihedral angle between C1-S of cysteine residue and C1-C2 
of the ligand (Figure 9, C).  
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  A        B             C 
Figure 9. Example of measurements collected between a b-carbon of a ligand and sulfur of a 
cysteine residue for each of the molecules docked noncovalently. (A – distance value in blue, B – 
planar angle in green, C – dihedral angle value in yellow).  
 
3.3 Covalent docking 
Once the receptor of the protein was set up, the residue which was involved in the 
formation of a covalent bond was selected (C146 and C797 for thymidylate synthase and EGFR 
protein kinase respectively). a,b-unsaturated carbonyl / Acrylamide Michael addition reaction 
was selected and added to the setup. Such entry enforced the covalent bond formation through a 
set reaction between the ligand and the cysteine residue. Chemical table of the molecules 
obtained from previously selected datasets was docked under thoroughness 10 with 1 best 
conformation automatically selected (Results section). Molecules without a matching warhead 
necessary for an addition reaction were excluded from further analysis.  
3.4 4D Docking 
First, all three structures of the thymidylate synthase protein were populated in ICM-Pro. 
Then, two of the structures were combined and superimposed on the third one. This action 
aligned selected proteins and allowed the combination of three receptor pockets into one. The 
docking simulation proceeded as mentioned above.   
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4. Ki/IC50 values 
Experimentally obtained Ki and IC50 values for the list of the ligands tested in this project 
were populated from the selected articles [5], [35]–[37] into the Microsoft Excel sheet in order to 
test the hypothesis.   
5. Analysis of 3 structures of TS and Papain 
Due to the absence of the measured Ki or IC50 values for the molecules tested with TS, 
actual bond formation for Molecules 4 and 12 and negative controls (Molecule 5 and all 
molecules tested with Papain) were used for the analysis. The data obtained with both 
thoroughness 3 and 10 were inspected. An attempt to eliminate false-positive results was made 
by using the values of distance and angle obtained through noncovalent docking and comparing 
them to their expected values. Expected distance allowing the covalent bond formation was 
estimated to be <5Å, while the best angle for bonding through the Michael addition reaction was 
predicted to be at around 90°. The best dihedral angle for the reaction could not be determined at 
this time.  
A paired t-test in Microsoft Excel was performed on the results obtained in thoroughness 
3 and 10 settings for each protein. The goal was to observe whether there was a significant 
difference between the values of a covalent score, distance, and angles when the thoroughness 
setting was increased.  
Additionally, the values for positive and negative controls were thoroughly compared to 
explore whether the software could predict their binding behavior during laboratory experiments.  
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6. Analysis of EGFR data 
6.1 Regression/Correlation analysis  
Based on the hypothesis, the covalent scores reported by ICM-Pro were expected to 
correlate with the distance, angle, dihedral angle or some combination of them obtained during 
non-covalent docking between the cysteine residue of the protein and the ligand. Since all 4 
categories are continuous data, the linear model function was used in R Studio (a computer 
program for statistical computing and graphics) [46] to examine the possibility of a linear 
relationship. Residuals, the difference between the predicted values of regression analysis and 
the actual values, were used to test the normality of the data. Visual examination of various 
diagnostic plots such as residuals vs fitted values, normal q-q plots of theoretical quantiles, scale-
location and residuals vs leverage in the relation to the covalent score was done.  P-value and R2 
value were examined using the summary command.  
Furthermore, the 3D plots with and without regression planes were created to visually 
search for patterns between variables outside of a linear model.  
6.2 T-test (one-sided and two-sided)  
Using the experimentally measured values of IC50, molecules were ranked from the 
smallest to the highest values. Upon considering the distribution of values (Figure 10) and its 
large range (from 1 to 50000), the decision was made to split the dataset based on the 
experimental IC50 values.  
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Figure 10. Distribution of IC50 values across molecules tested with EGFR. Values are given as a 
range in nM.  
 
 Since most of the data were gathered near the ends of the distribution with a small 
number of values in the middle, first and last 30% of the dataset were selected for the contrasting 
comparison of the in-silico measurements. The research question was to assess whether the in-
silico values of a noncovalent score, covalent score, distance, angle, and dihedral angle of 
inhibitors with very low IC50 values significantly differ from those, whose IC50 values are 
extremely high. The null hypothesis for that research question was “there is no difference 
between the in-silico values of a noncovalent score, covalent score, distance, angle, and dihedral 
angle among the inhibitors with low IC50 values and high IC50 values.”  
Before the statistical analysis of the data, each category was plotted using the Box and 
Whisker method to visually examine the differences. When the difference was visually observed, 
a t-test was run on the same category between the binders and non-binders to check for the 
significant difference of the means with an existing assumption for it to be greater or less. The 
61
1 1
10
[1.00, 12500.75] (12500.75, 25000.50] (25000.50, 37500.25] (37500.25, 50000.00]
Nu
m
be
r o
f m
ol
ec
ul
es
0
10
20
30
40
50
60
70
 31 
normality requirement for this test was omitted due to a large enough sample size (>20). One 
significant p-value was obtained and reported in the results section.  
Results:  
First Dataset of molecules tested with Thymidylate Synthase and Papain: 
Name Structure Name Structure 
Molecule 2  
 
Molecule 9 
 
Molecule 6 
 
Molecule 10 
 
Molecule 7 
 
Molecule 11 
 
Molecule 8 
 
Molecule 12 
 
Molecule 4 
Positive 
Control 
 
Molecule 5 
Negative 
Control 
 
 
 
Table 1. Molecules used in docking simulations of thymidylate synthase.  
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Table 2. Data obtained for three structures of thymidylate synthase and papain docked 
covalently and noncovalently with thoroughness set at 3.  
 
 
PDB ID Name TS binding Reactivity Covalent Score Noncovalent Score Distance C1-S Angle S-C1-C2 Dihedral Angle C2-C1-S-C(S)
Molecule2 NO MEDIUM -7.50 -9.22 4.2 153 28.3
Molecule4 YES LOW -12.84 -10.22 9.32 34.7 8.62
Molecule5 NO -18.99 -15.09 9.42 41.1 -82.1
Molecule6 NO -10.88 -10.76 8.9 63.5 -93.3
Molecule7 NO -4.93 -12.68 4.7 31.6 -44.8
Molecule8 NO HIGH -9.19 -15.66 4.88 65.8 -102
Molecule9 NO -9.37 -9.96 6.31 32 158
Molecule10 NO -9.70 -11.32 4.78 29.5 -79.8
Molecule11 NO MEDIUM -10.23 -14.48 7.09 71.6 50.1
Molecule12 YES MEDIUM -11.92 -12.03 4.62 56.4 -98.4
Molecule2 NO MEDIUM -5.61 -18.75 4.8 88.1 -134.0
Molecule4 YES LOW -14.98 -15.83 4.72 26.3 -59.1
Molecule5 NO -16.35 -13.94 4.78 27.1 -47.9
Molecule6 NO -9.61 -12.27 11.2 39.3 25.9
Molecule7 NO -7.499 -12.92 12.8 46.1 15.8
Molecule8 NO HIGH -12.6 -16.02 4.51 128 -150.0
Molecule9 NO -8.756 -14.50 6.82 34.5 -179.0
Molecule10 NO -6.899 -14.75 4.86 35.1 -1.2
Molecule11 NO MEDIUM -10.23 -14.12 4.69 29 -17.5
Molecule12 YES MEDIUM -16.53 -11.65 4.82 27.2 -34.2
Molecule2 NO MEDIUM -14.36 -16.93 4.00 48.8 -97.7
Molecule4 YES LOW -18.31 -22.31 4.12 45.4 -113
Molecule5 NO -18.98 -20.77 8.91 78.2 147
Molecule6 NO -14.30 -15.49 4.11 45.4 -96.2
Molecule7 NO -15.00 -14.96 8.38 44.3 147
Molecule8 NO HIGH -14.61 -16.51 8.75 68.4 150
Molecule9 NO -13.17 -13.19 4.53 34.4 170
Molecule10 NO -16.56 -19.67 8.80 68.2 150
Molecule11 NO MEDIUM -15.98 -21.93 8.54 58.8 148
Molecule12 YES MEDIUM -15.41 -16.99 8.89 80.4 145
Molecule 2 NO NONE -13.76 -14.79 7.3 116 21.3
Molecule 4 NO NONE -16.74 -18.96 4.03 47.8 -132
Molecule 5 NO NONE -17.77 -16.93 7.33 118 24.7
Molecule 6 NO NONE -13.75 -14.97 5.94 108 64.4
Molecule 7 NO NONE -17.01 -12.51 4.64 43.4 146
Molecule 8 NO NONE -11.97 -14.40 9.02 22.6 -176
Molecule 9 NO NONE -14.47 -13.38 7.53 109 27.2
Molecule10 NO NONE -16.15 -19.87 4.97 99.1 73.1
Molecule 11 NO NONE -14.08 -16.73 5.09 114 36
Molecule 12 NO NONE -12.19 -12.12 3.85 96.6 135
1F4B
1F4G
4KNZ
1PPN
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Table 3. Data obtained for three structures of thymidylate synthase and papain docked 
covalently and noncovalently with thoroughness set at 10.  
 
Molecules used for docking (Table 1) and three x-ray structures of thymidylate synthase 
and papain were analyzed. Both molecules 4 and 12 were experimentally reported to be covalent 
binders and were used as a positive control for this study. Molecule 5 was experimentally 
determined to be a non-binder and was used as a negative control. All molecules tested for a 
covalent bond with papain were reported to be non-binders. Separation of binders from non-
binders based on the covalent docking score as well as distance, angle, and dihedral angle 
PDB ID Name TS binding Reactivity Covalent Score Noncovalent Score Distance C1-S Angle S-C1-C2 Dihedral Angle C2-C1-S-C(S)
Molecule2 NO MEDIUM -7.989 -9.05 4.20 153.00 28.30
Molecule4 YES LOW -7.931 -9.51 9.32 34.80 8.32
Molecule5 NO -12.52 -14.90 9.44 39.70 -81.60
Molecule6 NO -10.93 -10.83 8.90 63.50 -93.30
Molecule7 NO -5.886 -12.79 4.70 31.60 -83.50
Molecule8 NO HIGH -9.946 -15.61 4.88 65.60 -102.00
Molecule9 NO -9.448 -10.01 6.31 32.00 158.00
Molecule10 NO -11.98 -12.46 8.63 138.00 -91.50
Molecule11 NO MEDIUM -10.35 -14.55 7.09 71.70 50.00
Molecule12 YES MEDIUM -14.52 -10.60 4.63 31.70 -90.50
Molecule2 NO MEDIUM -11.14 -18.77 4.8 88.1 -134
Molecule4 YES LOW -12.63 -13.30 4.72 25.2 -64.2
Molecule5 NO -9.03 -16.49 4.82 24.4 -67.4
Molecule6 NO -14.71 -12.33 11.2 39.1 -25.4
Molecule7 NO -6.93 -13.11 12.8 46.1 15.7
Molecule8 NO HIGH -12.57 -15.99 4.51 128 -149
Molecule9 NO -10.21 -15.72 8.04 92.4 115
Molecule10 NO -7.04 -18.21 6.22 46.8 -176
Molecule11 NO MEDIUM -12.52 -17.01 5.96 44.7 -172
Molecule12 YES MEDIUM -15.96 -8.12 3.69 67.9 -81.6
Molecule2 NO MEDIUM -14.35 -16.21 4.03 112.0 -128
Molecule4 YES LOW -18.57 -20.20 4.13 53.0 -109
Molecule5 NO -23.45 -20.45 8.83 69.0 149
Molecule6 NO -14.07 -16.82 4.21 48.9 -95.1
Molecule7 NO -14.47 -19.12 10.1 66.1 -175
Molecule8 NO HIGH -15.99 -16.66 8.75 68.4 150
Molecule9 NO -13.06 -13.16 8.64 63.0 156
Molecule10 NO -16.33 -20.62 8.81 68.1 150
Molecule11 NO MEDIUM -16.4 -21.57 8.55 52.8 148
Molecule12 YES MEDIUM -16.34 -17.28 8.89 80.4 145
Molecule 2 NO NONE -14.01 -15.95 5.69 107.0 67.9
Molecule 4 NO NONE -16.90 -18.97 4.04 47.1 -132
Molecule 5 NO NONE -16.98 -20.53 7.45 41.2 161
Molecule 6 NO NONE -15.53 -15.06 4.15 101.0 165
Molecule 7 NO NONE -17.29 -15.10 3.84 145.0 34.8
Molecule 8 NO NONE -13.34 -14.43 9.02 22.1 -176
Molecule 9 NO NONE -14.37 -13.09 7.53 109.0 27.2
Molecule 10 NO NONE -15.66 -18.44 6.45 127.0 -35.1
Molecule 11 NO NONE -14.09 -16.68 5.09 114.0 36
Molecule 12 NO NONE -20.45 -12.14 3.87 95.7 134
4KNZ
1PPN
1F4B
1F4G
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obtained from noncovalent docking failed regardless of thoroughness setting used (Table 2, 
Table 3). None of the noncovalent features differ significantly between thoroughness 3 and 
thoroughness 10 and resulted in p>0.05 when examined through a paired t-test.  
In thymidylate synthase, in two out of six total trials negative control Molecule 5 
presented with a better covalent docking score than both binders Molecule 4 and Molecule 12. 
Molecule 5 also scored better than one of the true binders in the other three out of six trials. An 
attempt to further differentiate between a true binder and a non-binder was unsuccessful due to 
the position of the best conformation of a negative control being located within a similar distance 
to that of a positive control in four out of six trials. Additionally, the values of an angle obtained 
through computer simulation studies significantly deviated from the predicted ones. Since the 
values were similar to that of a negative control in most of the cases, further differentiation 
between positive and negative controls based on the noncovalent docking features was 
impossible.  
When the same set of molecules was tested with papain, the thoroughness setting did not 
appear to be significant as well (p>0.05). Although all molecules were experimentally confirmed 
to be non-binders with papain, ICM-Pro reported values such as covalent score, distance, and 
angles did not aid in establishing them as false positives due to their wide range and their 
similarity to those of thymidylate synthase. Moreover, some of the noncovalent features 
indicated a potential binder with a distance of 3.87 Å and a planar angle of 95.7o, while none of 
the molecules form a covalent bond with papain in vitro (Molecule 12, Table 1).  
Furthermore, the effect of the pocket size of the protein on the noncovalent docking 
results was assessed and revealed no direct correlation. The data varied among large and small 
pockets.  
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When all three structures of thymidylate synthase were superimposed along with their 
active site pockets, 4D docking was performed and revealed similar results. Although positive 
control binders scored higher in this docking simulation than the negative control, some of the 
other non-binders also obtained a high score and could not be eliminated due to the distance and 
the angle of the warhead to the C146 being similar to those of other molecules (Table 4).  
Name TS binding VLS score (4D) 
Distance to 
C146 of 1F4B 
C1-S Angle in 
1F4B 
Molecule2 NO -16.91 9.39 53.7 
Molecule4 YES -19.76 4.45 63.1 
Molecule5 NO -15.92 3.91 107 
Molecule6 NO -16.55 9.39 53.9 
Molecule7 NO -20.54 7.7 66.3 
Molecule8 NO -14.17 9.08 42.5 
Molecule9 NO -15.47 8.77 87.9 
Molecule10 NO -17.14 11.3 59.4 
Molecule11 NO -17.89 9.37 54.7 
Molecule12 YES -17.81 9.57 48.5 
 
Table 4. Data obtained through a 4D docking of molecules into a combination of active site 
pockets of three structures of thymidylate synthase. Distance and angle values were calculated to 
the sulfur atom of C146 residue of the 1F4B structure of thymidylate synthase [40]. Binding 
information was obtained through experimental studies [34]. 
 
To test whether a small sample size was responsible for such results, a larger dataset of 
molecules was examined with EGFR to verify whether the experimental data would support the 
initial research hypothesis.  
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Larger Dataset of molecules tested with EGFR tyrosine kinase:  
Name Structure 
Cheng_1 
 
Lela_46 
 
1f 
 
 
Table 5. Example of structures of molecules used for computational studies with EGFR.  
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Name Score 
Noncovalent 
Score 
Covalent 
Distance 
C1-S 
S-C1-C2 
angle 
C2-C1-S-
C(S) 
Ki, 
nM 
IC50, nM 
1a -17.99 -24.28 8.09 134 32.5 
 
1600.00 
1b -32.85 -29.19 14.6 25 -163 
 
20.00 
1c -35.67 -17.47 9.82 21.8 -142 
 
690.00 
1d -23.02 -13.64 7.56 87.7 -88.5 
 
240.00 
1f -39.87 -13.83 14.3 82.2 168 
 
6600.00 
1g -23.62 -16.57 7.55 87.8 -88.5 
 
230.00 
1i -29.76 -13.12 8.55 63.6 62 
 
280.00 
1k -27.53 -15.74 7.61 84.2 -88 
 
220.00 
1m -33.15 -22.05 14.8 70 144 
 
6100.00 
1n -38.34 -34.74 4.16 65.1 -3.02 
 
270.00 
1o -41.61 -34.87 8.26 62.9 76.5 
 
10000.0
0 
1p -14.42 -28.19 15.6 69.5 65.1 
 
220.00 
1q -39.38 -18.74 14.5 24.2 -143 
 
40.00 
1r -34.84 -9.87 8.33 63 75.2 
 
10.00 
1s -39.38 -2.78 8.28 61.6 75.9 
 
1400.00 
1t -36.52 -13.08 9.52 23.9 -146 
 
920.00 
1u -46.47 -38.63 8.18 63.5 76.7 
 
1.00 
1v -44.66 -11.18 8.09 65 77.1 
 
3.00 
1w -27.39 -17.50 5.38 76.4 -50.4 
 
3.00 
1x -26.92 -19.91 7.93 57.8 -1.61 
 
2.00 
1y -13.40 -13.75 5.52 70.5 80.7 
 
210.00 
1z -27.52 -22.18 7.57 82.9 -63.9 
 
20.00 
Afatinib -32.86 -4.13 6.41 122 -33.6 0.16 7.30 
Canertinib -29.44 -16.61 6.82 114 46.1 0.11 3 
Cheng_1 -16.88 -11.34 10.5 46.1 61.4 4 13 
Cheng_10 -25.21 -17.32 10.2 70.6 130 2 4 
Cheng_11 -21.59 -20.02 12.1 53.6 46.4 14 27 
Cheng_12 -24.78 -23.13 11.9 39.4 134 3 13 
Cheng_13 -17.67 -16.10 15.8 73.8 162 590 50000 
Cheng_14 -26.58 -15.61 15.9 74.1 165 35 47 
Cheng_15 -23.08 -13.94 7.45 64.5 -56.2 8 45 
Cheng_16 -22.22 -13.44 7.34 64.6 -44.5 3 8 
Cheng_17 -18.03 -5.89 11.9 40.8 49.1 3 9 
Cheng_18 -22.49 -11.59 11.1 90.9 36.9 8 210 
Cheng_19 -19.36 -12.10 15.9 69.9 160 15 710 
Cheng_20 -22.09 -9.67 11.3 90 41.1 4 8 
Cheng_21 -21.19 -7.46 3.59 97.7 -41 32 120 
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Cheng_22 -29.69 -8.89 7.98 55.5 38.1 2 7 
Cheng_23 -18.68 -5.65 12 43.3 62.8 10 16 
Dacomitini
b 
-37.71 -7.23 12.1 76.7 120 0.63 10.30 
Lela_(R)-
32e 
-13.71 -17.05 10.2 25.2 102 
  
Lela_32a -22.67 -16.99 11 32.1 2.91 
 
50000.0
0 
Lela_32b -19.01 -17.75 8.02 118 -71.4 
 
50.00 
Lela_32c -26.40 -3.80 9.04 39.6 -12.6 
 
50000.0
0 
Lela_32d -19.17 -12.41 9.15 87.3 -68.7 
 
50000.0
0 
Lela_32f -9.74 -5.26 11.4 11.9 -10.9 
 
16460.0
0 
Lela_32g -15.25 -2.85 9.84 25.1 162 
 
2.00 
Lela_32h -21.28 -5.80 8.83 37.7 -163 
 
50000.0
0 
Lela_32i -25.30 0.46 11.4 23.7 -10 
 
6810.00 
Lela_32j -13.14 -8.43 7.51 69.6 49.7 
 
50000.0
0 
Lela_32k -13.82 -16.55 9.75 41.4 163 
 
50000.0
0 
Lela_32l -23.10 -12.46 15.4 74.3 13.4 
 
4.00 
Lela_32m -22.42 -0.50 15.3 49.9 117 
 
60.00 
Lela_32n -14.83 -2.05 11.3 13.9 -38.1 
 
50000.0
0 
Lela_32o -18.91 0.60 11.8 98.1 57.8 
 
50000.0
0 
Lela_32p -14.20 -9.05 6.78 77.2 -22 
 
32770.0
0 
Lela_32q -27.94 -15.01 16.1 27.6 139 
 
4.00 
Lela_32r -29.27 -14.19 15.2 50.6 174 
 
10.00 
Lela_32s -15.67 -2.20 15.6 43.9 -172 
 
50000.0
0 
Lela_43 -17.86 -18.27 10.4 33.5 -166 
 
1.39 
Lela_44 -16.47 -0.80 8.81 85.8 83.6 
 
2.18 
Lela_45 -15.97 -2.13 9.44 51.6 -112 
 
1.51 
Lela_46 -10.23 -1.41 5.87 103 -154 
 
2.11 
Lela_rac-
32e 
-15.44 -9.03 10.3 18.6 99.8 
 
20.00 
Molecule_1 -29.18 -23.83 5.96 164 -27.8 0.14 6.60 
Molecule_2 -30.13 -33.73 7.95 57 36.1 2.30 30.00 
Molecule_3 -23.98 -26.68 13.2 46.2 -164 4.00 210.00 
Molecule_5 -27.18 -27.61 7.64 64 38 30.00 850.00 
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Neratinib -12.62 -7.95 12.6 56.1 -169 0.14 9.40 
Osimertinib -29.34 -25.05 7.64 39.5 -106 
 
15 
Rociletinib -24.16 -3.75 15.8 64 114 
 
16 
WZ3146 -26.76 -14.14 9.76 43.7 -150 
 
5.00 
WZ4002 -19.54 -8.14 3.62 77 58.2 13.00 75.00 
WZ8040 -24.67 -4.93 6.28 17.9 167 
 
9.00 
 
Table 6. Data obtained through covalent and noncovalent docking of molecules with EGFR 
tyrosine kinase (PDB ID: 3w32 [12]). Ki and IC50 values for the molecules were obtained through 
experimental studies in vitro.   
 
First, a set of 74 molecules was examined for a regression/correlation relationship between 
the covalent docking score and distance with both planar and dihedral angles (Table 6). Although 
the linear model somewhat fit normality requirement (Figure 11), as represented by the fairly 
straight red lines in all 4 diagnostic plots, p-value of 0.8476>0.05 and extremely small R2 value 
signified no linear relationships between the variables. 
Figure 11. Visual verification of normality of the data for a linear model. A fairly horizontal line 
without distinct patterns in Residuals vs Fitted plot indicates a possibility of a linear relationship. 
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Residuals following the straight dashed line to some extent in the Q-Q plot shows the data to be 
normally distributed. Scale-Location plot shows some variance of the residuals. Residuals vs 
Leverage plot shows some extreme values (outliers) that influence the linear model.  
 
 Additionally, 24 molecules that had reported Ki values were also tested for a linear 
relationship between the variables with no success (p>0.05).  
Due to the absence of a linear relationship between the variables, the decision was made 
to split the dataset based on the experimental IC50 values, since most of the molecules had 
corresponding values available, and examine the datasets separately. Prospective inhibitors are 
required to possess high potency at low concentration values, therefore, any inhibitor with a high 
IC50 value would be rendered ineffective. Based on this assumption and because the majority of 
the IC50 values were located near the ends of the range, the dataset was split into 3 parts 
(30%,40%,30%). Data located in the middle of the distribution (40%) was ignored because their 
IC50 values did not signify either a true binder or a true non-binder. The first 30% of the data (21 
molecules) representing true positives with low IC50 values and the last 30% of the data (21 
molecules) representing true negatives with large IC50 values were examined individually and 
compared.  
A linear regression test was used to look for possible linear relationships between the 
variables and showed no correlation both within binders and non-binders (p>0.05).  
Further examination of a linear model in a 3D environment revealed no correlation within 
binders and non-binders. No visible patterns outside of a linear model were observed in the data. 
We then compared the values of the noncovalent score, covalent score, distance, planar 
and dihedral angles between binders and non-binders. First, a visual examination of the variables 
through the box plots was done. The only variable that visually differed between binders and 
non-binders was distance (Figure 12). 
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Figure 12. Distribution of distance values in Å between the warhead and C797 of EGFR (PDB 
ID: 3w32 [12]). Left, green – values for binders; right, orange – values for non-binders.  
 
The graph clearly shows that binders are located closer to the reactive cysteine residue that non-
binders. A one-tailed two-sample t-test was used to investigate whether the mean distance values 
among binders were less than that of the nonbinders and statistically significant. The test showed 
a p-value of 0.0296, which is significant. 
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Discussion:  
The results obtained through docking of 10 molecules with 3 different protein x-ray 
structures of thymidylate synthase and papain have shown that ICM-Pro is unable to correctly 
differentiate between the true binders and nonbinders in most of the cases regardless of the 
thoroughness setting used. Docking scores of 4D docking also appeared to be inadequate for the 
prediction of covalent bond formation. Additionally, the employment of values obtained through 
noncovalent docking has proved ineffective when used in a small sample size.  
The pocket size of the molecule may be responsible for the noncovalent docking results, 
since many more low-energy best scoring conformations may be available in a larger pocket 
compared to the smaller one. Nevertheless, the experimental data of this project does not support 
it, as the molecules docked in different pockets of various crystallographic structures of 
thymidylate synthase have shown similar results.  
While ICM-Pro may predict noncovalent conformations of the ligand more accurately, as 
represented by a wider range of scores, a great % error in covalent docking is still seen in a larger 
sample of molecules tested with EGFR. Covalent scores were expected to correlate with 
experimental data of inhibitory concentration of the molecules (lower covalent score – lower IC50 
value). However, no such trend has been observed. Therefore, a deeper insight into the 
mechanism of covalent docking and reaction mechanisms of covalent inhibition is required to 
improve available in silico tools.   
A slight difference in distance between true binders and nonbinders appeared to be the 
only way to differentiate between them in the study of EGFR. Further research can be done on a 
much larger sample among various proteins to examine whether the results are consistent 
throughout several structures and at a larger scale. Additionally, noncovalent docking with 
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distance restraints that would fix the ligand at a certain position allowing for little distance 
flexibility could provide more insight on the importance of distance in docking.  
Due to the wide range of the values of planar and dihedral angles between the cysteine 
residue and the ligand, these values did not aid in establishing true binders and nonbinders.  
This means that when docked noncovalently the position of the warhead of true covalent 
inhibitors is closer to the reactive cysteine residue than that of nonbinders, while also having 
varying values of planar and dihedral angles.  
Conclusion:  
This study has investigated a possible way to limit the number of false positives and false 
negatives when large datasets of molecules are screened for potential inhibitory interactions with 
the protein. The value of distance obtained through noncovalent docking can be further 
investigated in additional in silico simulations and potentially used as a filter to lower the 
number of molecules tested in-vitro for potential interactions and, subsequently, refine and 
economize the process of finding prospective breakthroughs that can treat the worst of human 
illnesses.  
Acknowledgments:  
I would like to thank my mentor Dr. Jean Gaffney for continuous encouragement and 
support throughout this project, Dr. Olga Lavinda and Dr. Timothy Cardozo at NYU Langone 
Medical Center for their experience and guidance in the field of computational chemistry and 
providing resources necessary for the completion of this project. Additionally, I would like to 
thank Dr. Andrew Orry of Molsoft LLC for expert help throughout computational studies, my 
readers Dr. Orrette Wauchope and Dr. Pablo Peixoto for their insightful comments and support, 
Baruch College and the Department of Natural Sciences for the encouragement in research.    
 44 
References:  
[1] “Data Access - Compressed Mortality File,” 28-Feb-2019. [Online]. Available: 
https://www.cdc.gov/nchs/data_access/cmf.htm. [Accessed: 15-Nov-2019]. 
[2] G. Bethune, D. Bethune, N. Ridgway, and Z. Xu, “Epidermal growth factor receptor 
(EGFR) in lung cancer: an overview and update,” J. Thorac. Dis., vol. 2, no. 1, pp. 48–51, 
Mar. 2010. 
[3] B. Alberts, Molecular biology of the cell, Sixth edition. New York, NY: Garland Science, 
Taylor and Francis Group, 2015. 
[4] R. S. Herbst, “Review of epidermal growth factor receptor biology,” Int. J. Radiat. Oncol. 
Biol. Phys., vol. 59, no. 2 Suppl, pp. 21–26, 2004, doi: 10.1016/j.ijrobp.2003.11.041. 
[5] H. Cheng et al., “Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-
yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-
2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-
Containing EGFR Mutants,” J. Med. Chem., vol. 59, no. 5, pp. 2005–2024, Mar. 2016, doi: 
10.1021/acs.jmedchem.5b01633. 
[6] J. Singh, R. C. Petter, T. A. Baillie, and A. Whitty, “The resurgence of covalent drugs,” 
Nat. Rev. Drug Discov., vol. 10, no. 4, pp. 307–317, Apr. 2011, doi: 10.1038/nrd3410. 
[7] D. J. Jollow, J. R. Mitchell, W. Z. Potter, D. C. Davis, J. R. Gillette, and B. B. Brodie, 
“Acetaminophen-induced hepatic necrosis. II. Role of covalent binding in vivo,” J. 
Pharmacol. Exp. Ther., vol. 187, no. 1, pp. 195–202, Oct. 1973. 
[8] A. V. Fuentes, M. D. Pineda, and K. C. N. Venkata, “Comprehension of Top 200 
Prescribed Drugs in the US as a Resource for Pharmacy Teaching, Training and Practice,” 
Pharm. Basel Switz., vol. 6, no. 2, May 2018, doi: 10.3390/pharmacy6020043. 
[9] A. Vasudevan et al., “Covalent binders in drug discovery,” in Progress in Medicinal 
Chemistry, vol. 58, Elsevier, 2019, pp. 1–62. 
[10] “Molsoft L.L.C.: ICM-Pro.” [Online]. Available: http://www.molsoft.com/icm_pro.html. 
[Accessed: 22-Nov-2019]. 
[11] J. McMurry, D. S. Ballantine, C. A. Hoeger, and V. E. Peterson, Fundamentals of general, 
organic, and biological chemistry, Eighth edition in SI units-Global edition. Boston 
Columbus Indianapolis, New York: Pearson, 2017. 
[12] Y. Kawakita et al., “Design and synthesis of novel pyrimido[4,5-b]azepine derivatives as 
HER2/EGFR dual inhibitors,” Bioorg.Med.Chem., vol. 21, pp. 2250–2261, 2013, doi: 
10.2210/pdb3w32/pdb. 
[13] G. N. Lewis, “THE ATOM AND THE MOLECULE.,” J. Am. Chem. Soc., vol. 38, no. 4, 
pp. 762–785, Apr. 1916, doi: 10.1021/ja02261a002. 
[14] D. Jeffreys, Aspirin: the remarkable story of a wonder drug, Pbk. ed. London: Bloomsbury, 
2005. 
[15] “Alexander Fleming Discovery and Development of Penicillin - Landmark,” American 
Chemical Society. [Online]. Available: 
https://www.acs.org/content/acs/en/education/whatischemistry/landmarks/flemingpenicillin
.html. [Accessed: 19-Jun-2019]. 
[16] “Omeprazole: Uses, Side Effects & Dosage Guide,” Drugs.com. [Online]. Available: 
https://www.drugs.com/omeprazole.html. [Accessed: 25-Jun-2019]. 
 45 
[17] R. A. Bauer, “Covalent inhibitors in drug discovery: from accidental discoveries to avoided 
liabilities and designed therapies,” Drug Discov. Today, vol. 20, no. 9, pp. 1061–1073, Sep. 
2015, doi: 10.1016/j.drudis.2015.05.005. 
[18] S. Aykul and E. Martinez-Hackert, “Determination of half-maximal inhibitory 
concentration using biosensor-based protein interaction analysis,” Anal. Biochem., vol. 508, 
pp. 97–103, Sep. 2016, doi: 10.1016/j.ab.2016.06.025. 
[19] A. Scarpino, G. G. Ferenczy, and G. M. Keserű, “Comparative Evaluation of Covalent 
Docking Tools,” J. Chem. Inf. Model., vol. 58, no. 7, pp. 1441–1458, 23 2018, doi: 
10.1021/acs.jcim.8b00228. 
[20] R. D. Little, M. R. Masjedizadeh, O. Wallquist, and J. I. Mcloughlin, “The 
IntramolecularMichael Reaction,” in Organic Reactions, John Wiley & Sons, Inc., Ed. 
Hoboken, NJ, USA: John Wiley & Sons, Inc., 1995, pp. 315–552. 
[21] “12.10: Nucleophilic Addition to α, β- Unsaturated Carbonyl Compounds,” Chemistry 
LibreTexts, 05-Sep-2014. [Online]. Available: 
https://chem.libretexts.org/Bookshelves/Organic_Chemistry/Map%3A_Essential_Organic_
Chemistry_(Bruice)/12%3A_Carbonyl_Compounds_II%3A_Reactions_of_Aldehydes_and
_Ketones_%E2%80%A2_More_Reactions_of_Carboxylic_Acid_Derivatives/12.10%3A__
Nucleophilic_Addition_to_%CE%B1%2C_%CE%B2-
_Unsaturated_Carbonyl_Compounds. [Accessed: 28-Nov-2019]. 
[22] H. M. Kumalo, S. Bhakat, and M. E. S. Soliman, “Theory and applications of covalent 
docking in drug discovery: merits and pitfalls,” Mol. Basel Switz., vol. 20, no. 2, pp. 1984–
2000, Jan. 2015, doi: 10.3390/molecules20021984. 
[23] K. M. Ferguson, “Structure-based view of epidermal growth factor receptor regulation,” 
Annu. Rev. Biophys., vol. 37, pp. 353–373, 2008, doi: 
10.1146/annurev.biophys.37.032807.125829. 
[24] C. V. Dang, E. P. Reddy, K. M. Shokat, and L. Soucek, “Drugging the ‘undruggable’ 
cancer targets,” Nat. Rev. Cancer, vol. 17, no. 8, pp. 502–508, Aug. 2017, doi: 
10.1038/nrc.2017.36. 
[25] G. Sliwoski, S. Kothiwale, J. Meiler, and E. W. Lowe, “Computational Methods in Drug 
Discovery,” Pharmacol. Rev., vol. 66, no. 1, pp. 334–395, Dec. 2013, doi: 
10.1124/pr.112.007336. 
[26] S. Kalyaanamoorthy and Y.-P. P. Chen, “Structure-based drug design to augment hit 
discovery,” Drug Discov. Today, vol. 16, no. 17–18, pp. 831–839, Sep. 2011, doi: 
10.1016/j.drudis.2011.07.006. 
[27] X.-Y. Meng, H.-X. Zhang, M. Mezei, and M. Cui, “Molecular docking: a powerful 
approach for structure-based drug discovery,” Curr. Comput. Aided Drug Des., vol. 7, no. 
2, pp. 146–157, Jun. 2011, doi: 10.2174/157340911795677602. 
[28] “Molsoft L.L.C.: ICM Docking and Screening.” [Online]. Available: 
https://www.molsoft.com/docking.html. [Accessed: 15-Nov-2019]. 
[29] D. P. Kroese, T. Brereton, T. Taimre, and Z. I. Botev, “Why the Monte Carlo method is so 
important today,” WIREs Comput. Stat., vol. 6, no. 6, pp. 386–392, 2014, doi: 
10.1002/wics.1314. 
[30] P. J. Tummino and R. A. Copeland, “Residence Time of Receptor−Ligand Complexes and 
Its Effect on Biological Function,” Biochemistry, vol. 47, no. 20, pp. 5481–5492, May 
2008, doi: 10.1021/bi8002023. 
 46 
[31] P. A. Jackson, J. C. Widen, D. A. Harki, and K. M. Brummond, “Covalent Modifiers: A 
Chemical Perspective on the Reactivity of α,β-Unsaturated Carbonyls with Thiols via 
Hetero-Michael Addition Reactions,” J. Med. Chem., vol. 60, no. 3, pp. 839–885, Feb. 
2017, doi: 10.1021/acs.jmedchem.6b00788. 
[32] “What is an inhibitory constant (Ki) and how does it relate to understanding drug 
interactions?” [Online]. Available: https://www.ebmconsult.com/articles/inhibitory-
constant-ki-drug-interactions. [Accessed: 15-Nov-2019]. 
[33] B. T. Burlingham and T. S. Widlanski, “An Intuitive Look at the Relationship of Ki and 
IC50: A More General Use for the Dixon Plot,” J. Chem. Educ., vol. 80, no. 2, p. 214, Feb. 
2003, doi: 10.1021/ed080p214. 
[34] R. H. Nonoo, A. Armstrong, and D. J. Mann, “Kinetic template-guided tethering of 
fragments,” ChemMedChem, vol. 7, no. 12, pp. 2082–2086, Dec. 2012, doi: 
10.1002/cmdc.201200404. 
[35] P. A. Schwartz et al., “Covalent EGFR inhibitor analysis reveals importance of reversible 
interactions to potency and mechanisms of drug resistance,” Proc. Natl. Acad. Sci. U. S. A., 
vol. 111, no. 1, pp. 173–178, Jan. 2014, doi: 10.1073/pnas.1313733111. 
[36] G. Lelais et al., “Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-
enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a 
Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and 
Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell 
Lung Cancers,” J. Med. Chem., vol. 59, no. 14, pp. 6671–6689, 28 2016, doi: 
10.1021/acs.jmedchem.5b01985. 
[37] J. Engel et al., “Structure-Guided Development of Covalent and Mutant-Selective 
Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor 
Receptor,” J. Med. Chem., vol. 60, no. 18, pp. 7725–7744, 28 2017, doi: 
10.1021/acs.jmedchem.7b00515. 
[38] “SMILES Tutorial | Research | US EPA.” [Online]. Available: 
https://archive.epa.gov/med/med_archive_03/web/html/smiles.html. [Accessed: 27-Jan-
2020]. 
[39] R. P. D. Bank, “RCSB PDB: Homepage.” [Online]. Available: https://www.rcsb.org/. 
[Accessed: 15-Nov-2019]. 
[40] D. A. Erlanson et al., “Site-directed ligand discovery.,” Proc.Natl.Acad.Sci.USA, vol. 97, 
pp. 9367–9372, 2000, doi: 10.2210/pdb1f4b/pdb. 
[41] R. P. D. Bank, “RCSB PDB - Obsolete - 4KNZ,” Thymidylate Synthase Ternary Complex 
DUMP CB3717, doi: 10.2210/pdb4knz/pdb. 
[42] R. W. Pickersgill, G. W. Harris, and E. Garman, “Structure of Monoclinic Papain at 1.60 
Angstroms Resolution,” Acta CrystallogrSectB, vol. 48, pp. 59–67, 1992, doi: 
10.2210/pdb1ppn/pdb. 
[43] S. Planken et al., “Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-
pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) 
through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting 
Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR.,” J Med Chem, vol. 60, 
pp. 3002–3019, 2017, doi: 10.2210/pdb5ug8/pdb. 
[44] E. J. Hanan et al., “4-Aminoindazolyl-dihydrofuro[3,4-d]pyrimidines as non-covalent 
inhibitors of mutant epidermal growth factor receptor tyrosine kinase.,” 
Bioorg.Med.Chem.Lett., vol. 26, pp. 534–539, 2016, doi: 10.2210/pdb5edp/pdb. 
 47 
[45] “Molsoft L.L.C.: ICM Pocket Finder.” [Online]. Available: 
http://www.molsoft.com/icmpocketfinder.html. [Accessed: 15-Nov-2019]. 
[46] “RStudio.” [Online]. Available: https://rstudio.com/. [Accessed: 28-Nov-2019]. 
 
